• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕金森病患者健康相关生活质量恶化的预测因素:DATATOP试验结果

Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.

作者信息

Marras Connie, McDermott Michael P, Rochon Paula A, Tanner Caroline M, Naglie Gary, Lang Anthony E

机构信息

Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.

出版信息

Mov Disord. 2008 Apr 15;23(5):653-9; quiz 776. doi: 10.1002/mds.21853.

DOI:10.1002/mds.21853
PMID:18076084
Abstract

The aim of this study was to investigate factors associated with decline in health-related quality of life in Parkinson's disease, by a retrospective cohort study from referral centers in Canada and the United States. Subjects were patients with early Parkinson's disease (N = 362) enrolled in a clinical trial of deprenyl (selegiline) and tocopherol (DATATOP) and followed prospectively. The main outcome measure was change in health-related quality of life using SF-36 Mental and Physical Component Summary scores. The mean interval between SF-36 measurements was 1.7 +/- 0.1 years, beginning 5 to 6 years after enrolment into the trial. In multivariable analysis, baseline Hamilton Depression Scale scores and self-rated cognitive function were associated with subsequent decline in Physical Component Summary scores, while older age and Schwab and England activities of daily living scores were associated with decline in Mental Component Summary scores. The Postural Instability Gait Disorder score was the only variable found to decline concurrently with HRQOL. Our results suggest that depression, self-rated cognitive function, and one's degree of functional independence are predictors of subsequent changes in HRQOL. Our focus in clinical care needs to be broadened beyond assessing and treating Parkinsonism, recognizing the impact of mood, cognition and function on HRQOL.

摘要

本研究旨在通过对加拿大和美国转诊中心的一项回顾性队列研究,调查与帕金森病患者健康相关生活质量下降相关的因素。研究对象为参加了去甲丙咪嗪(司来吉兰)和生育酚(DATATOP)临床试验的早期帕金森病患者(N = 362),并对其进行前瞻性随访。主要结局指标是使用SF-36精神和身体成分汇总评分来衡量健康相关生活质量的变化。SF-36测量之间的平均间隔为1.7 +/- 0.1年,从入组试验5至6年后开始。在多变量分析中,基线汉密尔顿抑郁量表评分和自评认知功能与随后身体成分汇总评分的下降相关,而年龄较大以及施瓦布和英格兰日常生活活动评分与精神成分汇总评分的下降相关。姿势不稳步态障碍评分是唯一发现与健康相关生活质量同时下降的变量。我们的结果表明,抑郁、自评认知功能以及功能独立程度是健康相关生活质量后续变化的预测因素。我们在临床护理中的关注点需要从评估和治疗帕金森症扩大到认识情绪、认知和功能对健康相关生活质量的影响。

相似文献

1
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.帕金森病患者健康相关生活质量恶化的预测因素:DATATOP试验结果
Mov Disord. 2008 Apr 15;23(5):653-9; quiz 776. doi: 10.1002/mds.21853.
2
Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.普拉克索与左旋多巴起始治疗对早期帕金森病的长期影响。
Arch Neurol. 2009 May;66(5):563-70. doi: 10.1001/archneur.66.1.nct90001.
3
Predictors and course of health-related quality of life in Parkinson's disease.帕金森病中与健康相关生活质量的预测因素及病程
Mov Disord. 2008 Jul 30;23(10):1420-7. doi: 10.1002/mds.22121.
4
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.持续使用司来吉兰(丙炔苯丙胺)对左旋多巴治疗的帕金森病的影响:帕金森病去甲丙咪嗪和生育酚抗氧化治疗试验的随机安慰剂对照扩展研究
Ann Neurol. 2002 May;51(5):604-12. doi: 10.1002/ana.10191.
5
A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.两项大型帕金森病临床试验队列中治疗阈值的比较。
Mov Disord. 2009 Dec 15;24(16):2370-8. doi: 10.1002/mds.22828.
6
Depressive symptoms impacting on health-related quality of life in early Parkinson's disease: results from Chinese L-dopa exposed cohort.抑郁症状对早期帕金森病患者健康相关生活质量的影响:来自中国左旋多巴暴露队列的结果
Clin Neurol Neurosurg. 2009 Nov;111(9):733-7. doi: 10.1016/j.clineuro.2009.07.001. Epub 2009 Aug 8.
7
Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.帕金森病的生存率:DATATOP队列的13年随访
Neurology. 2005 Jan 11;64(1):87-93. doi: 10.1212/01.WNL.0000148603.44618.19.
8
Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life.帕金森病患者感知到的参与度和满意度:对治疗决策及生活质量的影响。
Mov Disord. 2005 May;20(5):616-9. doi: 10.1002/mds.20393.
9
Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.帕金森病早期治疗试验(DATATOP)中的死亡率:一项多中心试验。帕金森研究小组。
Ann Neurol. 1998 Mar;43(3):318-25. doi: 10.1002/ana.410430309.
10
The relationship of pain and health-related quality of life in Korean patients with Parkinson's disease.韩国帕金森病患者疼痛与健康相关生活质量的关系。
Acta Neurol Scand. 2009 Jun;119(6):397-403. doi: 10.1111/j.1600-0404.2008.01114.x. Epub 2008 Oct 22.

引用本文的文献

1
Approaches for treating neuropsychiatric symptoms in Parkinson's disease: a narrative review.帕金森病神经精神症状的治疗方法:一项叙述性综述
Ther Adv Neurol Disord. 2025 May 26;18:17562864251336903. doi: 10.1177/17562864251336903. eCollection 2025.
2
Investigation of the validity, reliability and psychometric properties of the Turkish version of the Ottawa sitting scale in patients with Parkinson's disease.帕金森病患者中土耳其语版渥太华坐姿量表的效度、信度及心理测量学特性研究。
Sci Rep. 2025 Jan 21;15(1):2628. doi: 10.1038/s41598-025-87006-7.
3
Psychiatric predictors of quality of life in Parkinson's disease: A three-year longitudinal study.
帕金森病患者生活质量的精神预测因素:一项为期三年的纵向研究。
J Neurol Sci. 2024 Nov 15;466:123248. doi: 10.1016/j.jns.2024.123248. Epub 2024 Sep 18.
4
A comprehensive multivariate analysis of the center of pressure during quiet standing in patients with Parkinson's disease.帕金森病患者安静站立时压力中心的综合多变量分析。
J Neuroeng Rehabil. 2024 Apr 23;21(1):59. doi: 10.1186/s12984-024-01358-1.
5
Hyperglycemia affects axial signs in patients with Parkinson's disease through mechanisms of insulin resistance or non-insulin resistance.高血糖通过胰岛素抵抗或非胰岛素抵抗机制影响帕金森病患者的轴性体征。
Neurol Sci. 2024 May;45(5):2011-2019. doi: 10.1007/s10072-023-07273-y. Epub 2023 Dec 26.
6
The effects of medical comorbidity, cognition, and age on patient-reported outcomes in Parkinson's disease.医学合并症、认知功能和年龄对帕金森病患者报告结局的影响。
Parkinsonism Relat Disord. 2023 Nov;116:105892. doi: 10.1016/j.parkreldis.2023.105892. Epub 2023 Oct 10.
7
Association of caregiver strain with the trajectory of quality of life in Parkinson's disease.照料者负担与帕金森病患者生活质量轨迹的关联。
Parkinsonism Relat Disord. 2023 Mar;108:105292. doi: 10.1016/j.parkreldis.2023.105292. Epub 2023 Jan 23.
8
The pathobiological basis of depression in Parkinson disease: challenges and outlooks.帕金森病中抑郁的病理生物学基础:挑战与展望。
J Neural Transm (Vienna). 2022 Dec;129(12):1397-1418. doi: 10.1007/s00702-022-02559-5. Epub 2022 Nov 2.
9
Gait Characteristics Analyzed with Smartphone IMU Sensors in Subjects with Parkinsonism under the Conditions of "Dry" Immersion.使用智能手机 IMU 传感器分析帕金森病患者在“干浸”条件下的步态特征。
Sensors (Basel). 2022 Oct 18;22(20):7915. doi: 10.3390/s22207915.
10
Effects of Multimodal Rehabilitation on the Activities of Daily Living, Quality of Life, and Burden of Care for Patients with Parkinson's Disease: A Randomized Control Study.多模式康复对帕金森病患者日常生活活动、生活质量及护理负担的影响:一项随机对照研究
Healthcare (Basel). 2022 Sep 27;10(10):1888. doi: 10.3390/healthcare10101888.